Pharma's AI ROI gap isn't strategy or tech; it's the missing workforce qualification step every other regulated capability requires.

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

In this episode, we discuss AI drug discovery hype, agent security risks, and why pharma's AI workforce bets remain unproven.

Manufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Two

Three regulatory actions are converging to move biologics, gene therapy, and the ATMP platform forward quickly

Regulatory Actions Impacting Biologics

Modernizing infrastructures, record drug approvals, and harmonization were all positive regulatory advancements in July 2026.

Regulatory Roundup—July 2026

This episode of Pharma Fundamentals provides an introduction to hold times in biopharmaceutical manufacturing and how they differ from hold times in small-molecule drug manufacturing.

Pharma Fundamentals: An Introduction to Hold Times in Biopharmaceuticals

The use of artificial intelligence is facing harder questions of governance and data quality

PharmTech Weekly Roundup—July 17, 2026

Three regulatory actions are converging to move biologics, gene therapy, and the ATMP platform forward quickly, say Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, technical, Parexel.

How evolving regulatory expectations are reshaping pharma development and manufacturing.

Drug Digest April 2026

FDA approves Lilly's once-weekly insulin efsitora

The FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin indicated alongside diet and exercise to control high blood sugar in adults with type 2 diabetes.

 It is designed to deliver steady basal insulin over seven days, which cuts annual injections from about 365 with a once-daily basal insulin to 52.

The US decision follows approvals by the EMA, Mexico's Federal Commission for the Protection against Sanitary Risks, and Japan's Pharmaceuticals and Medical Devices Agency.

 It also makes efsitora the second once-weekly basal insulin available to US prescribers. 

Novo Nordisk expanded its metabolic portfolio when the FDA approved its once-weekly insulin icodec (Awiqli) for type 2 diabetes on the strength of ONWARDS phase III data.

"For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients' day-to-day experience managing type 2 diabetes," said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, in a press release.

 "Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes."

The approval is based on the phase III QWINT program.

 It enrolled more than 3,400 adults with type 2 diabetes across four studies covering three groups: patients new to insulin, patients switching from daily basal insulin, and patients who also use mealtime insulin. In each trial, efsitora met the primary endpoint of noninferior A1C reduction compared with once-daily insulin glargine or insulin degludec. QWINT-1 also tested a simplified fixed-dose escalation of 100, 150, 250, and 400 units, which could make it easier to start insulin.

Safety was similar to the daily comparators.

 Efsitora is not indicated for type 1 diabetes because of an increased risk of severe hypoglycemia. Common side effects include hypoglycemia, allergic and injection-site reactions, lipodystrophy, rash, swelling of the hands and feet, and weight gain.

Efsitora's weekly profile comes from its molecular design.

 It is a fusion protein that joins a novel single-chain insulin variant to the Fc domain of a human immunoglobulin G2 antibody, and this structure gives it a half-life of roughly 15 to 16 days. That Fc-fusion architecture puts efsitora closer to engineered biologics than to conventional recombinant insulin analogs, which affects expression, purification, and analytical control strategies. Icodec takes a different approach: it binds to albumin, forming an inactive depot that releases drug slowly over the week.

The drug product also raises formulation and device considerations.

The KwikPen will come in 500 units/mL and 1,000 units/mL concentrations, delivering up to 400 and 800 units per injection, respectively. That is far above the 100 units/mL comparators used in QWINT. The labeling emphasizes preventing dosing errors. It warns patients not to dial the maximum dose unless prescribed, not to withdraw product with a syringe, and to check labels to avoid mix-ups. When one injection carries a week of drug, human factors engineering and labeling become central to combination-product risk management.

The launch also draws on a manufacturing network 

. The company's plans to expand insulin active-ingredient, delivery-device, and cartridge capacity across 

Indianapolis, Puerto Rico, France, and China.

How Is Lilly Reshaping Its Domestic Manufacturing Capabilities?

Efsitora's approval lands days after Lilly broke ground on a $6.5 billion API facility in Houston, its fifth domestic ingredient site among ten US manufacturing locations announced since 2020.

 The plant will produce orforglipron (Foundayo), an oral glucagon-like peptide-1 receptor agonist. Because it is a small molecule rather than a peptide, it relies on more established and readily scalable technologies. The site will also make oligonucleotides and other advanced therapeutics, with machine learning, AI, and digitally integrated systems embedded to support right-first-time execution.

Eli Lilly and Company. U.S. Food and Drug Administration (FDA) approves Lilly’s Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment. Published September 24, 2026. Accessed September 24, 2026. 

https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-fda-approves-lillys-onswiktm

Eli Lilly and Company. Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020. Published September 21, 2026. Accessed September 24, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lilly-breaks-ground-houston-one-ten-us-manufacturing-sites

Articles

FDA approval of insulin efsitora alfa-gobe provides a once-weekly basal insulin option for adults with type 2 diabetes, reducing injection frequency from daily to 52 annually. Authorization was supported by the phase III QWINT program (n>3,400), showing noninferior A1C lowering versus insulin glargine or degludec across insulin-naïve patients, switchers, and those using prandial insulin. Efsitora’s Fc-fusion design yields a 15–16-day half-life, driving distinct CMC, device, and dosing-error risk considerations.

The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.

Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark

Senior Director
Education, Outreach, and Digital Experience
Open Biopharma Research and Training Institute

Florin Muraru, Gourav Pandey, and Rick Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP settings.

PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP

Multi-agent AI is edging toward the pharmaceutical shop floor, and the question of where the human gate belongs in a validated GxP environment is no longer theoretical. In Part 2 of the three-part 

first episode of the PharmTech AI Pulse Check

 video series, Christopher Cole, associate editorial director, 

, asks for insights from co-hosts Florin Muraru, an independent regulatory advisor; Gourav Pandey, R&D quality lead at Takeda; and Richard Jaenisch, senior director at Open Biopharm (

Watch Part 1: Fixing AI Slop at the Source

). The conversation opens with a recent benchmark test in which OpenAI agents reportedly built a private coordination channel days after it was shut down, and asks how pharma's segregation-of-duties playbook should respond.

Muraru argues that letting agents talk while requiring human sign-off before any action is realistic in a validated environment, but only if the action is the GxP-relevant step. He draws a firm line at batch release, noting, "The agents reasoning together is fine, but an agent releasing a batch without a human decision absolutely is out of limit." The real problem, he explains, emerges when inter-agent conversation becomes the basis of a decision, because that exchange then qualifies as a record carrying data integrity, retention, and review obligations. He adds a further regulatory layer: a self-modifying multi-agent system lacks a stable baseline to validate against, and validation underpins trust in computerized systems in GxP environments.

Pandey adds that data integrity culture in pharma treats even a sticky note as a GxP document, so an inter-agent discussion that was never captured is a serious gap. He points to two agents building a deviation report, one drafting the investigation while the other works through facts, and observes that machines can do a great deal of the work but a signature must belong to a real, answerable person. Jaenisch raises the architecture question: hash-chain audit logs and permission gates help, yet the benchmark agents went around those gates. He favors a monitoring agent over human reviewers because no one has time to read a week and a half of dense output.

The discussion then turns to Baidu's newly open-sourced model that parses entire multi-page documents, including tables, layout, and reading order, in a single pass. Pandey sees an opening for the decades of scanned records, handwritten logbooks, and research lab books sitting in third-party archival facilities. Because the model is open source, companies can deploy it in-house with a GPU and pair it with a knowledge graph linking terminated programs, old batches, and compliance reports to vendors, molecules, solvents, and raw materials. He finds particular promise for research, noting, "We have so many failed experiments that may have insightful information for the molecule which never progressed further down the line in the pipeline."

Muraru cautions that the moment those documents underpin a reconstructed batch record, data migration, or regulatory submission, the system leaves research territory and requires validation, since an OCR error can become a data integrity error. His advice is to use the tool for looking back at records but to verify against the originals. Jaenisch adds that many-to-many document analysis has historically been prohibitively expensive, that someone must define ground-truth documents so the model can tell signal from scrap, and that OCR across older, varied document types is a concern because generative AI reflects its training data. He places meaningful adoption a year or two away and quips that governing this architecture will create new jobs.

Videos

Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

Ask the Expert: Post-Approval Changes

Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice on how to handle post-approval changes in this episode of Ask the Expert. The drug manufacturing process is never static, explains Schmitt, and therefore, companies should anticipate future changes from either production volume, process optimization, or technological innovation. The key question is how much of this can be anticipated and addressed before filing.

Schniepp outlines the regulatory mechanisms available, focusing on the system in the United States. With prior-approval changes, companies wait for the FDA to sign-off before implementing. For changes being effected in 30 days (CBE-30), companies can proceed after a 30-day waiting period absent an objection by the FDA objection. CBE is an even faster pathway rarely used today. She notes companies sometimes register alternative methods (eg, both high-performance liquid chromatography and ultra-high-pressure liquid chromatography) at filing time to build in flexibility. Schniepp recommends comparability protocols as a useful tool for managing scale-up changes.

According to Schmitt, pre-approval submissions typically prioritize speed to market, though companies should also consider requesting pre-approval for anticipated changes to avoid the time and cost burdens of post-approval processes, particularly costly Type II variations in Europe. However, resource constraints often limit how much forward planning occurs before approval, because teams are focused on the approval itself.

Schniepp highlights annual reportable changes (eg, certain equipment upgrades or method changes with demonstrated comparability) as another avenue requiring less regulatory scrutiny, urging companies to carefully study relevant guidance documents.

Schniepp emphasizes that a company’s risk tolerance should drive its change-management strategy; some organizations are highly risk-averse and prefer prior approval, while others are more comfortable leveraging annual reports for faster implementation. Both experts agree there’s no one-size-fits-all approach; each company must develop its own change management strategy based on its specific risk appetite and resources.

Click the video above to watch Sue and Siegfried answer the question: “We are coming to a regulatory filing, and we know there's a possibility of post-approval changes being pre-approved. Do you have any advice?”

Susan J. Schniepp is distinguished fellow at Nelson Labs and a member of 

Siegfried Schmitt is vice president, Technical at Parexel and a member of 

In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.

Pills and inhalers for asthma, bronchitis, lungs diseases | Image Credit: ©barmalini -stock.adobe.com

On September 23, 2026, AstraZeneca announced that asthma maintenance treatment, Trixeo, was approved in the European Union.

 The European Commission approved Trixeo Aerosphere (budesonide/ glycopyrronium/ formoterol fumarate dihydrate, 320/28.8/10 mcg) for the maintenance treatment of asthma in patients aged 12 and older whose disease remains inadequately controlled on medium-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy. Trixeo is the first triple-combination therapy approved in the EU for asthma delivered in a single inhaler, extending a product line already approved for chronic obstructive pulmonary disease (COPD) in more than 90 countries.

The decision was based on the recommendation from the European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use (CHMP),

 and came after results from phase 3 KALOS and LOGOS trials, 2 replicate, randomized, double-blind studies spanning roughly 4300 patients over 24 to 52 weeks. Trixeo produced statistically significant lung-function improvements and a significant reduction in severe exacerbation rates compared with inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapy, including benefit in patients with no exacerbations in the prior year, with no new safety signals and onset within 5 minutes of the first dose.

“Today’s approval in asthma builds on Trixeo’s established role in improving outcomes in patients with COPD,” Ruud Dobber, executive vice president and president, BioPharmaceuticals Business Unit, AstraZeneca, said in a press release.

 “This means we can now bring the benefits of a single-inhaler triple-combination therapy to people aged 12 years and older in Europe whose asthma remains uncontrolled on dual inhaled therapy.”

Trixeo is built on AstraZeneca's proprietary Aerosphere formulation, a pressurized metered-dose inhaler (pMDI) platform that suspends 3 active ingredients as porous microparticles for consistent co-delivery in a single actuation. Producing a fixed-dose triple therapy at commercial scale is markedly more demanding than a single- or dual-agent inhaler: it requires tightly controlled particle engineering, precise dose uniformity across 3 actives, specialized canister-filling lines, and rigorous in-use and stability testing across shelf life. With nearly 43 million people living with asthma in Europe and about 4 million new diagnoses annually, and roughly half of patients remaining uncontrolled on dual therapy, a new eligible population now enters the addressable market for this class, adding pressure on fill-finish capacity, valve and actuator component supply, and analytical testing throughput industry-wide.

The timing also intersects with the industry's shift away from high-global-warming-potential (GWP) propellants used in most pMDIs. AstraZeneca has already 

secured EU approval to reformulate Trixeo

 with a next-generation, near-zero-GWP propellant, and manufacturers across the respiratory space are racing to requalify formulations, canisters, and filling equipment ahead of tightening environmental rules in Europe and elsewhere.

 An asthma indication broadens the volume base over which that propellant transition must be executed, raising the stakes and opportunity for contract development and manufacturing organizations (CDMOs) and component suppliers with pMDI capability.

There are competitive and supply-chain implications, too. AstraZeneca's move deepens its lead in single-inhaler triple therapy for airways disease at a moment when generic-drug manufacturers are advancing copies of earlier-generation combination inhalers and competitors are developing biologics and small-molecule alternatives for respiratory disease, as 

PharmTech coverage of European biotechs reshaping respiratory disease has noted.

 It also lands amid AstraZeneca's broader manufacturing expansion, including a multibillion-dollar US investment program with new chronic-disease capacity in Virginia — a reminder that regulatory wins like this one tend to arrive alongside, and reinforce the case for, continued capital investment in dedicated inhaler lines.

For contract manufacturers and component suppliers specifically, an asthma label expansion for an established pMDI product typically brings demand signals well before launch: higher forecasts for canisters, metering valves, and actuators; added stability and in-use testing lots for the new patient population; and often renegotiated long-term supply agreements to de-risk the larger volume base. Combined with the parallel push toward near-zero-GWP propellants, manufacturers evaluating device platforms or capacity investment in inhaled respiratory products now have a clearer signal that European regulators will expand triple-combination pMDI therapy beyond COPD into asthma, a potential precedent that formulation teams and CDMOs weighing new or expanded pMDI filling lines will likely watch closely.

1. Trixeo approved in the EU for the maintenance treatment of asthma. Press release. AstraZeneca. September 23, 2026. 

https://www.astrazeneca.com/media-centre/press-releases/2026/trixeo-approved-in-the-eu-for-the-maintenance-treatment-of-asthma.html

2. CHMP. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026. Press release. EMA. July 24, 2026. 

https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026

3. EMA. First reformulation of an inhaled medicine with environmentally friendly gas propellant. Press Release. July 25, 2025. 

https://www.ema.europa.eu/en/news/first-reformulation-inhaled-medicine-environmentally-friendly-gas-propellant

4. Barton C. European biotechs reshaping respiratory disease. 

https://www.pharmtech.com/view/european-biotechs-reshaping-respiratory-disease

5. AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D. Press release. AstraZeneca. July 21, 2025. 

https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html

The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.

EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy

Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River. Dr. Aleksandra Zuraw is a board-certified senior toxicologic pathologist at Charles River Laboratories and a long-time leader in digital pathology and image analysis. She has worked extensively with AI tools and digital workflows since the early stages of her career, contributing to the development and validation of image analysis solutions across several organizations. Dr. Zuraw is the coauthor of several peer-reviewed publications on digital pathology and image analysis, and the author of the book 

"Digital Pathology 101: Everything you need to know to start and continue your digital pathology journey."

 Originally from Poland, she completed her pathology training in Berlin, Germany, and has worked across six countries. She also founded the online educational platform Digital Pathology Place, where she creates content and training materials that help bridge the gap between digital pathology innovation and practical application. Through her global perspective and commitment to education, Dr. Zuraw continues to shape the integration of AI and digital pathology in veterinary pathology.

Pharma Fundamentals: Digital Pathology in Drug Development, Part 1

Digital pathology is shifting from a lab-bench convenience to a validated, GxP-governed data system, which may have implications for drug manufacturing and quality organizations. In this episode of 

 Pharma Fundamentals series, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development and explains that digitization’s value is how it can convert a one-time tissue observation into a persistent, traceable data source that follows the sample from collection through processing, scanning, quality control, and final image. Pathology itself touches nearly every stage of the development processes, says Zuraw, from lead selection and tox/safety work through clinical biomarker studies to post-market diagnosis; therefore, a connected digital pipeline pays off at multiple points.

Traceability, Validation, and AI-Ready Data

That traceability requires the same validation as any computerized system used in a GxP environment. Charles River validated its digital pathology pipeline under 21 

 Part 11, running a non-inferiority study led by 2 board-certified veterinary pathologists to confirm digital slides lose no diagnostic detail versus glass, tested across H&E, immunohistochemistry, and special stains, and across multiple species.

Zuraw dispels 2 misconceptions relevant to any organization piloting artificial intelligence (AI). One misconception is that “AI-readiness” is a property of the data rather than the organization, requiring a defined use case, validated tools, and standard operating procedures, repeated per tool and use case. The other misconception is that FDA guidance lags the technology, when in fact 

 applies the same risk-based, context-of-use framework good laboratory practice (GLP) organizations already use.

AI-Readiness Misconception (Image created in Claude)

For drug manufacturers, this type of automation reshapes staffing and workflow. Linking slide production to scanning can automate manual checks currently performed by several people per slide, but Zuraw notes this may worry technicians who fear losing varied, skilled work to hours of digital slide review. In addition, moving pathology data at scale is its own IT and compliance project; a single image can rival a 2-hour HD video in file size. Peer review illustrates the stakes: what once meant shipping glass slides and traveling to share a microscope now happens almost instantaneously online, provided both sides are on validated, interoperable systems. When a partner or sponsor isn't at the same level of digital or GLP readiness, a familiar challenge in multi-site and contract organization relationships, the organization must choose between a documented compliance exception or falling back to physical media.

CLICK THE VIDEO ABOVE TO WATCH THE EPISODE

Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers Guidance for Industry.

https://www.fda.gov/media/168431/download

Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products

Draft Guidance for Industry and Other Interested Parties. 

January 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

Dr. Aleksandra Zuraw is a board-certified senior toxicologic pathologist at Charles River Laboratories and a long-time leader in digital pathology and image analysis. She has worked extensively with AI tools and digital workflows since the early stages of her career, contributing to the development and validation of image analysis solutions across several organizations. Dr. Zuraw is the coauthor of several peer-reviewed publications on digital pathology and image analysis, and the author of the book 

 Originally from Poland, she completed her pathology training in Berlin, Germany, and has worked across six countries. She also founded the online educational platform Digital Pathology Place, where she creates content and training materials that help bridge the gap between digital pathology innovation and practical application. 

In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.

Cheryl Barton is director of PharmaVision, 

Stockholm old town city skyline, cityscape of Sweden | Image Credit: ©f11photo -stock.adobe.com

Sweden continues as a leader in early-stage life science innovation.

 The country is recognized for its dynamic, venture-supported biotech companies that target a diverse range of therapeutic areas and diagnostic solutions, including central nervous system (CNS) and neurology (AlzeCure Pharma, BioArtic AB), cell and gene therapies (Anocca AB, Asgard Therapeutics), immuno-oncology (Aligator Biosciences, Neogap Therapeutics AB), and rare diseases (Calliditas Therapeutics AB, Swedish Orphan Biovitrum AB). Since June 2025, investment in Swedish biotechs has surged, with a heavy focus on out-licensing, rights issues, and collaborations with strategic pharma partners including Eli Lilly, Foundation Medicine (Roche), and QuantumCell, amongst others (

Swedish Biotech Companies that Have Recently Attracted Venture Capital and Pharmaceutical Investments

Sweden Has a Strong R&D Base and Thriving Life Science Sector

According to the Royal Swedish Academy of Engineering Sciences, Sweden has a strong research and development (R&D) base.

 Long-term investments in research infrastructure such as SciLifeLab, MaxIV, and the European Spallation Source (ESS) offer valuable opportunities for research in life sciences and related fields. These facilities are also a key strength in attracting talented researchers to Sweden.

 AstraZeneca has a major presence in Sweden, has a large impact on the Swedish economy, and accounted for 5% of Sweden’s total product exports in 2023. 

What Are Some Swedish Biotechs to Watch Out for?

Sweden's life sciences industry is thriving. More than 150 small- to medium-sized companies are actively developing pharmaceuticals for human use and have products in clinical development.

Several biotechs have products in late-stage clinical trials, including Affibody Medical AB, BioArtic AB, Camurus, Diamyd Medical Aktiebolag, Dilafor AB, Dizlin Pharmaceuticals AB, Ilya Pharma AB, Infant Bacterial Therapeutics AB, Immedica Pharma AB, Sarcomed AB, Swedish Orphan Biovitrum (Sobi) AB and Vivesto AB.The Swedish pipeline is broad and spans various modalities (eg, advanced therapy medicinal products [ATMPs], biomolecules, and small molecules) and therapeutic areas (eg, autoimmune/immunology, cardiovascular, endocrinology/metabolism, infection, oncology, and neurology/CNS) (

 Swedish Drug Discovery and Development Project, by Stage and Modality, 2025 (Figure courtesy of the author)

Figure 2: Swedish drug discovery and development project, by therapy area and modality, 2025 (Figure courtesy of the author)

The following are some Swedish biotech companies to keep an eye on.

is a clinical-stage radiopharmaceutical company working on next-generation radioligand therapies (RLTs) to target tumors precisely. The company has created novel small (6 kDa) therapeutic proteins, called Affibody molecules, which specifically bind to target cells. In May 2026, the company published positive phase 2b/3 data from its lead programme with Izokibep in psoriatic arthritis, and it dosed the first patient in its phase 1 trial with ABY-271, a RLT targeting HER2-positive metastatic breast cancer.

 On February 17, 2026, Affibody’s licensee Rallybio Corporation announced positive results from its phase 1 confirmatory study with RLYB116, a once-weekly, small-volume, subcutaneously injected complement factor 5 (C5) inhibitor, based on the Affibody platform

 is a biotech firm specializing in oncology. It halted development of mitazalimab in 2026 due to it non-commercial viability in the pancreatic cancer market. The company will now concentrate on HLX22, an HER2-targeting antibody in phase 3 trials for breast cancer and other solid tumors. Additionally, at AACR 2026, they reported encouraging data on HLX49, a HER2 biparatopic antibody-drug conjugate that contains HER2 binding domains from HLX22.

 In August 2024, the company announced a rights issue of SEK 125.6 million (UD$13 million) and entered into bridge loan agreements totaling SEK 19 million (US$2 million) to secure near-term liquidity.

 is a private biopharmaceutical company developing drugs for heart failure. Founded on research from Karolinska Institutet, it aims to improve heart muscle contractility. Its lead program, AC01, is an oral calcium-sensitizing agent licensed from Helsinn and is now in development for heart failure. A phase 1b/2a study showed proof of concept in HFrEF patients, supporting further development of this promising drug.

 The company has raised more than US$40 million (SEK 432 million) across multiple funding rounds, attracting investment from Novo Holdings, Pureos Bioventures, and Sound Bioventures, Flerie, Industrifonden, and others to develop its product pipeline.

was founded in 2014 and is a clinical-stage biopharmaceutical company developing T cell receptor-modified T cell therapy (TCR-T) immunotherapies. It has created a pipeline of T-cell immunotherapies by combining its novel approach to T-cell biology, cutting-edge biotechnologies, and integrated software. In August 2025, the company raised SEK440 million (US$166 million) in Series D financing, attracting investment from AMF, Mellby Gård, and Ramsbury to advance the development of its pancreatic cancer candidate, ANOC-001, the first non-viral, gene-edited TCR-T cell therapy targeting KRAS G12V mutations in pancreatic ductal adenocarcinoma (PDAC).

 In June 2026, the company initiated its Phase I VDAR trial. It has forged a strategic platform licensing agreement for cell engineering technology with MaxCyte and competes with Moderna and Jazz Pharmaceuticals in the genetic engineering space.

, founded in 2018, is a private biotech company specializing in cell reprogramming technologies. Its flagship program, AT-108, is an off-the-shelf gene-based cancer immunotherapy designed to reprogram tumor cells into cDC1-like antigen-presenting cells. This approach aims to work synergistically with immune checkpoint blockade (ICB) to generate a robust anti-tumor response. The therapy has demonstrated promising results in murine animal models.

The company has received funding from the Eurostars-2 joint program, with co-funding from EUREKA member countries and the European Union Horizon 2020 Framework Programme, and from the EIC Women in Tech program, with funding from the Horizon Europe program.

was established in 2003 and focuses on improving treatment for neurodegenerative diseases by enhancing delivery across the blood-brain barrier (BBB). The company developed Leqembi, which uses its proprietary Brain Transporter technology. In June 2026, BioArctic signed a US$30 million collaboration with Eli Lilly to apply its Brain Transporter technology to one of Lilly’s neurodegenerative drug candidates

In July 2026, Eisai received FDA approval for Leqembi (lecanemab), a weekly subcutaneous injection indicated for early Alzheimer’s disease. The medication utilizes BioArtics BrainTransporter technology and is scheduled for launch in August 2026.

Founded in 2008 by Dr Karl Tryggvason and his son, Dr Kristian Tryggvason, the company focuses on developing animal-free laminin-based cell culture tools that support the growth of pluripotent stem cells and other primary cells. In September 2025, it partnered with Cell X Technologies to integrate its laminin reagents (Biolaminin) with Cell X’s Celligent platform, enhancing the reproducibility of iPSC production.

 In April 2026, the EIB provided the company with a €20 million loan to further develop laminin technologies, supporting the advancement of next-generation cell therapies.

 In May 2026, Biolamina partnered with Cytochroma to leverage its technology to create iPSC-derived cells for drug discovery and disease modelling, supporting regulatory efforts to reduce animal testing and encourage new approach methodologies (NAMs).

 was founded in 2004 and focuses in creating specialized pharmaceuticals. Its main product candidate, nefecon (sold as Kinpeygo /Tarpeyo), is a delayed-release form of budesonide designed to treat IgA nephropathy (IgAN), an inflammatory kidney disease. The firm is also researching setanaxib, a NOX1/NOX4 inhibitor for solid tumors and fibrotic diseases, where early results are promising. Calliditas has partnered with Everest Medicines and gained approval from China’s NMPA to use nefecon for primary IgAN in at-risk adults. Moreover, Viatris Japan, its partner, announced a phase 3 trial for nefecon in Japan, starting July 4, 2024. The company has also collaborated with TADA Arzneimittel AG and filed with the MHRA to upgrade Kinpeygo from conditional to full marketing authorization. It has raised SEK 324 million (US$ 34 million) and secured a US$75 million loan from Kreos Capital.

founded in 1991, is a global biopharmaceutical firm dedicated to creating and marketing innovative, long-acting medicines for patients with severe and chronic conditions. It uses its proprietary FluidCrystal technology—a lipid-based drug delivery system—to develop injectable depots that deliver sustained medication levels over days to months. The company has partnered with Eli Lilly to develop and commercialize four long-acting incretins, and with Gubra to create a long-acting treatment for hypoparathyroidism

founded in 2017, specializes in developing anti-inflammatory and pain-relief drugs. In October of that year, it acquired the OX-MPI development program from Orexo AB, which included several selective and potent microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors, such as vipoglanstat (GS-248), originating from Boehringer Ingelheim. In March 2019, the company acquired additional mPGES-1 inhibitors from Acturum Real Estate AB, and advanced 1 of these agents, GS-073 (which originated from AstraZeneca), to phase 1 clinical trials in 2020. Recently, Gesynta decided to focus on developing vipoglanstat for endometriosis. The company has completed 3 funding rounds and raised more than SEK 607 million (US$229 million), attracting investments from Hadean Ventures, Innovestor Life Science, Industrifonden, and Linc to support its product pipeline. Gesynta Pharma has received support from Karolinska Institutet Innovation AB, Novo Nordisk Foundation, Swelife, and VINNOVA–Sweden’s Innovation Agency.

was established in 2020 and operates as a privately owned biotechnology company. It focuses on creating advanced brain-targeting treatments, leveraging its proprietary VHH antibodies capable of crossing the BBB. In June 2025, the company signed a licensing deal with Chiesi to use its BBB technology for developing CNS-targeted enzyme replacement therapies for lysosomal storage disorders.

 In February 2026, it formed a strategic partnership with OliX Pharmaceuticals to develop further siRNA delivery for central nervous system (CNS) disorders.

is a clinical-stage biotech company focused on creating personalized cancer immunotherapies that use the patient’s own cells. Their method is based on 2 proprietary technologies: PIOR and EpiTCer. PIOR combines patient DNA sequencing data with machine learning to identify tumor-specific mutations, while EpiTCer expands T cells that recognize and attack these specific tumor features. In February 2026, the company raised SEK87 million (US$9.6 million) in funding led by Society funds. These funds will support the development of its pTTL (personalized Tumor Trained Lymphocytes) therapy for patients with advanced colorectal cancer.

 It has also received a grant from Medtech4Health to advance its autoimmune research.

) is a global biopharma company that is developing life-saving therapies for people living with rare diseases. It has a broad portfolio of drugs targeting hematology and immunology. In February 2026, it completed the acquisition of US-based Arthrosi Therapeutics to strengthen its gout franchise and gain access to pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in 2 fully recruited global phase 3 clinical studies for the potential management of progressive and tophaceous gout, with results expected to read out in 2026

Sobi has forged various partnerships, including entering into a licensing deal with Innate Pharma to initiate the TELLOMAK-3 confirmatory phase 3 study in cutaneous T-cell lymphoma (CTCL) with lacutamab.

 In August 2026, it repurchased all issued Class C shares, paying SEK122 million (US$13 million); the company will convert these shares to common shares.

Future Opportunities for Investment in Swedish Biotechs

Sweden’s Life Science industry, with annual sales of about SEK 474 billion (US$50 billion), has become one of the nation's leading engines of growth (see 

). Recently, government investments have increased, bolstered by a vibrant private sector that makes up about three-quarters of the country's R&D expenditure.

 In April 2026, the Swedish government initiated a national project called Swe Trial to establish a unified framework for clinical trials. The goal is to simplify the process, boost capacity and reduce barriers to enhance the country's competitiveness in healthcare, research, and industry. Biobank Sweden has provided SEK10 million (US$1.1 million) to fund the project, and the Swedish Medical Products Agency (Läkemedelsverket) will supervise it.

Swedish biotech companies have a strong and wide-ranging product pipeline, providing pharma with considerable opportunities to invest in early-stage startups and innovative technologies. This can help pharma grow its own pipeline and create the next wave of groundbreaking therapies.

Swedish Biotech Companies to Keep an Eye On.

SwedenBIO. The Swedish Drug Discovery and Development Pipeline 2026. SwedenBio. 2026.

https://swedenbio.se/wp-content/uploads/2025/10/lowres-the-swedish-drug-discovery-and-development-pipeline-2026.pdf

Johansson A, et al. Swedish Science Barometer 2025/26. Vetenskap & Allmänhet. 2026. Accessed September 8, 2026. 

https://vetenskapallmanhet.se/wp-content/uploads/2026/02/varapport2025_4-English.pdf 

Government Offices in Sweden. A concerted effort for excellence, long-term competitiveness, and increased patient benefit: National life sciences strategy. New objectives. 2026. Accessed September 8, 2026. 

government.se/contentassets/79e61ed6d1334ebba5a1a8bd5bb295f3/a-concerted-effort-for-excellence-long-term-competitiveness-and-increased-patient-benefit/

Positive 52-week phase 2b/3 data of Izokibep in psoriatic arthritis to be presented at EULAR 2026. Press release. Affibody Medical AB.May 21, 2026. 

https://www.affibody.se/press/positive-52-week-phase-2b-3-data-of-izokibep-in-psoriatic-arthritis-to-be-presented-at-eular-2026/

First patient dosed in part b of phase 1 study with affibody’s radioligand therapy candidate ABY-271 in HER2-positive metastatic breast cancer. Press release. Affibody Medical AB. May 28, 2026. 

https://www.affibody.se/press/first-patient-dosed-in-part-b-of-phase-1-study-with-affibodys-radioligand-therapy-candidate-aby-271-in-her2-positive-metastatic-breast-cancer/

Affibody’s licensee Rallybio announces positive data for RLYB116 phase 1 study demonstrating complete and sustained inhibition of terminal complement. Press release. Affibody Medical AB. February 17, 2026. 

https://www.affibody.se/press/affibodys-licensee-rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement/

Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026 . Press release. Alligator Bioscience. April 23, 2026. 

https://alligatorbioscience.se/en/mfn_news/alligator-bioscience-comments-on-henlius-presentation-of-hlx49-preclinical-data-at-aacr-2026/

Alligator Bioscience shares crash 73% after dropping key drug program By Investing.com. Press release

https://uk.investing.com/news/stock-market-news/scott-bizily-4d-molecular-therapeutics-chief-legal-officer-sells-8176-93CH-4858908

AnaCardio´s phase 1b/2a GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) published in 

.Press release. AnaCardio. June 24, 2026. 

https://anacardio.com/anacardios-phase-1b-2a-goal-hf1-study-in-patients-with-heart-failure-and-reduced-ejection-fraction-hfref-published-in-the-lancet/

AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure. Press release.AnaCardio. January 9, 2025. 

https://anacardio.com/anacardio-secures-usd-19-million-to-advance-ac01-development-for-heart-failure-and-shares-positive-result-from-phase-1b-study/

Anocca raises SEK 440 million to advance clinical trial targeting pancreatic cancer. Press release.Anocca. September 29, 2025.

https://www.anocca.com/company/news/anocca-raises-sek-440-million-to-advance-clinical-trial-targeting-pancreatic-cancer

Asgard Therapeutics announces oral presentation at ASGCT 2026, showcasing advanced preclinical data on AT-108 – its first-in-class, off-the-shelf, gene-based cancer immunotherapy. Press release. April 28, 2026. 

https://www.asgardthx.com/asgard-therapeutics-announces-oral-presentation-at-asgct-2026-showcasing-advanced-preclinical-data-on-at-108-its-first-in-class-off-the-shelf-gene-based-cancer-immunotherapy/

European Innovation Council Transition–accelerating 40 groundbreaking technologies from lab to market readiness. Press release. European Innovation Council. January 22, 2025. 

https://eic.ec.europa.eu/news/european-innovation-council-transition-accelerating-40-groundbreaking-technologies-lab-market-2025-01-22_en

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter technology. Press release. BioArctic. June 22, 2026. 

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer’s disease. Press release. BioArtic. July 13, 2026. 

https://www.bioarctic.com/en/fda-approves-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-as-a-starting-dose-for-early-alzheimers-disease/

Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics. Press release. BioLamina. September 29, 2025.

https://biolamina.com/newsroom/cell-x-technologies-and-biolamina-enter-a-collaboration-to-advance-standardization-in-ipsc-based-therapeutics/

Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment. Press release. BioLamina. April 16, 2026. 

Sweden is reinforcing its position as a European hub for early-stage life science, supported by deep R&D infrastructure (SciLifeLab, MaxIV, ESS) and a strong industrial anchor in AstraZeneca. Since mid-2025, financing and deal activity have accelerated, emphasizing out-licensing, rights issues, and strategic collaborations with large pharma and diagnostics partners. A broad, modality-diverse pipeline spans CNS, immuno-oncology, ATMPs, and rare disease assets, with multiple late-stage programs. Government-backed SweTrial aims to streamline and scale national clinical-trial execution.

Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.

Featured Content

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Manufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Two

Regulatory Actions Impacting Biologics

Regulatory Roundup—July 2026

Pharma Fundamentals: An Introduction to Hold Times in Biopharmaceuticals

PharmTech Weekly Roundup—July 17, 2026

Regulatory Actions Impacting Biologics

Drug Digest April 2026